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Abstract
Background: Whilst a large number of malaria antigens are being tested as candidate malaria
vaccines, a major barrier to the development of an effective vaccine is the lack of a suitable human
adjuvant capable of inducing a strong and long lasting immune response. In this study, the ability of
AFCo1, a potent T and B cell adjuvant based on cochleate structures derived from meningococcal
B outer membrane proteoliposomes (MBOMP), to boost the immune response against two
Plasmodium falciparum antigens, merozoite surface protein 4 (MSP4) and 5 (MSP5), was evaluated.
Methods: Complete Freund's adjuvant (CFA), which is able to confer protection against malaria
in animal MSP4/5 vaccine challenge models, was used as positive control adjuvant. MSP4 and 5-
specific IgG, delayed-type hypersensitivity (DTH), T-cell proliferation, and cytokine production
were evaluated in parallel in mice immunized three times intramuscularly with MSP4 or MSP5
incorporated into AFCo1, synthetic cochleate structures, CFA or phosphate buffered saline.
Results: AFCo1 significantly enhanced the IgG and T-cell response against MSP4 and MSP5, with
a potency equivalent to CFA, with the response being characterized by both IgG1 and IgG2a
isotypes, increased interferon gamma production and a strong DTH response, consistent with the
ability of AFCo1 to induce Th1-like immune responses.
Conclusion: Given the proven safety of MBOMP, which is already in use in a licensed human
vaccine, AFCo1 could assist the development of human malaria vaccines that require a potent and
safe adjuvant.
Background
Infection with Plasmodium parasites is one of the most
important health problems of tropical countries, with 500
million clinical cases and over 1 million malaria deaths
annually. Notwithstanding that multiple species can infect
humans;  Plasmodium falciparum is responsible for the
majority of malaria deaths[1]. The development of an
effective malaria vaccine remains a critical public health
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objective given that vector control is not always easy or
effective and drug resistant strains are increasingly emerge
[2-5]. Although an enormous amount of knowledge on
malaria pathogenesis has been accumulated over recent
years, no highly protective vaccine has yet emerged. As a
result of the improvement of antigen identification and
expression technologies, many promising malaria anti-
gens have been cloned and evaluated, but unfortunately
this has not translated into clinical success. Proteins
exposed on the surface of the asexual blood stage [6],
including merozoite surface proteins (MSP)1, MSP2,
MSP4, MSP5 and MSP8 represent potential targets to gen-
erate asexual blood stage vaccines [2,6-12]. MSP4 and
MSP5 are currently in late-stage preclinical development
and GMP manufacture in anticipation of human clinical
testing http://www.malariavaccine.org/rd-research-pro
grams.php. Both proteins are encoded by a tandem region
on chromosome 2 of P. falciparum and share structural
similarities, including a glycosylphosphatidylinositol
anchor (GPI) and an epidermal growth factor-like
domain that is essential for correct structural folding [13-
15]. In particular, MSP5 is highly conserved among P. fal-
ciparum isolates with a lack of significant antigen diversity,
a desirable property for a vaccine candidate [16,17]. For
these vaccines to advance to the clinic, they will need to be
combined with a suitable vaccine adjuvant, and as part of
this project we are screening candidate adjuvants for this
purpose.
Part of the difficulty in developing malaria vaccines is the
need for a sufficiently potent yet safe human adjuvant to
make the vaccine effective. Aluminium hydroxide (alum)
or water in oil emulsions, e.g. Montanide ISA720, have
been the most commonly used adjuvants in malaria vac-
cine trials to date. These adjuvants have largely failed to
generate protective immunity and in the case of Monta-
nide have proved to be considerably reactogenic [18].
Plasmodium antigens may induce a suppressor immune
response thereby assisting parasite survival and making it
more difficult to induce effective vaccine immunity [19-
21]. In animal vaccine challenge studies, complete Fre-
und's adjuvant (CFA) stands out for its ability to induce
protective immunity to malaria in situations where alum
or Montanide are ineffective.
Although CFA is too toxic for human use, this suggests
that the development of an effective malaria vaccine will
require more potent human adjuvants than those cur-
rently available [22]. To date, greatest success with a
malaria vaccine has been seen with RTS,S, a CSP-derived
antigen developed by GSK Biologicals in collaboration
with the Walter Reed Army Institute of Research. The
RTS,S vaccine is formulated in AS02A, a proprietary GSK
adjuvant which contains the immune stimulants QS21
and monophosphoryl lipid A in an oil emulsion. In Afri-
can field trials RTS,S vaccine provided partial short-term
protection against malaria and limited disease severity,
with the ASO2A adjuvant being potentially at least one
factor contributing to the success of this vaccine [23-25].
The importance of the adjuvant selection for malaria vac-
cine success suggests that the type of the immune response
generated by a malaria vaccine may be at least as impor-
tant as the quantum of the immune response in determin-
ing vaccine efficacy. Although rodent models are useful to
assess malaria antigen candidates, no small animal mod-
els are able to test actual protection against P. falciparum
challenge [26].
However, a combined humoral and cellular immune
response including induction of complement fixing anti-
bodies and cytotoxic T cells against the vaccine antigen is
thought to be important for protection against malaria
[27-30]. Preclinical studies with recombinant MSP4/5, the
single homologue of both MSP4 and MPS5 in Plasmodium
yoelii (Py), a species of rodent malaria, have shown that it
requires combination with a strong Th1 adjuvant such as
CFA to provide malaria protection [31]. As CFA is too
toxic for human use, as part of the development program
for MSP4 and MSP5 as malaria vaccine candidates various
adjuvants have been tested for their suitability for inclu-
sion in clinical trials of these vaccines. The development
of a novel adjuvant based on the structural transformation
into cochleate structures (AFCo1, Adjuvant Finlay Coch-
leate 1) of proteoliposomes (PL) extracted from the outer
membrane of Neisseria meningitidis B has been previously
reported [32,33]. AFCo1 consists of a highly stable com-
plex of Ca2+, proteins and lipids forming a compact mul-
tilayered tubular structure, which can accommodate new
antigens from different sources thus allowing its use as an
antigen delivery system [32,34,35]. AFCo1 also contain
several Neisseria-derived pathogen associated molecular
patterns (PAMPs) within its structure, namely porin pro-
teins and lipopolysaccharide (LPS), which powerfully
activate the innate and adaptive immune systems and,
thereby, provide AFCo1 with strong adjuvant properties
[32]. Adjuvant properties of AFCo1 have been previously
demonstrated using model antigens, including egg albu-
min (OVA), Leishmania major proteins and the gD2 glyco-
protein from herpes simplex virus type 2)[36]. These
experiments confirmed that AFCo1 induced a potent
immune Th1 response characterized by high levels of anti-
gen-specific IgG, class switching from IgG1 to IgG2a, and
increased antigen-specific T cells producing IFNγ [37].
Mice immunized with L. major antigens plus AFCo1 were
protected, suggesting the ability of AFCo1 to modulate the
natural induction of a Th2-type responses by L. major,
resulting in a Th1 switch and a substantial decrease of the
progression of lesions after challenge [32].Malaria Journal 2009, 8:35 http://www.malariajournal.com/content/8/1/35
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In the current study, the ability of AFCo1 adjuvant to
enhance the immune response against recombinant
MSP4 and MSP5 from P. falciparum was tested. These stud-
ies confirm the utility of AFCo1 to enhance a Th1-type
response to incorporated vaccine antigen and this raises
the possibility of using AFCo1 as an adjuvant for MSP-
based vaccines in future human trials.
Methods
Antigens
The full-length MSP4 and MSP5 sequences lacking the
secretion signals and the GPI attachment signals were
expressed in E. coli with a C-terminal hexahistidine tag.
The fusion proteins were purified with TALON metal
affinity resin according to the manufacturer's instructions.
The purify and integrity of the proteins were assessed on
SDS-PAGE gels stained with Coomassie blue, and the con-
centration of the proteins were measured with the Bio-Rad
Bradford assay [9,14].
Adjuvants
Both MSP4 and MSP5 proteins were formulated inde-
pendently with three adjuvants: incorporated into AFCo1
and Synthetic Cochleate Structure (SCS) or emulsified in
CFA; generating six formulations to be tested in animal
experiments.
AFCo1 consists of a highly stable complex of lipid mem-
branes from PL and Ca2+ that is formed when PL is slowly
exposed to CaCl2 buffer solution through a dialysis proc-
ess. The PL from N. meningitidis serogroup B (Cu385,
B4:P1.15, 19, L3, 7, 9) used for obtaining AFCo1 was
obtained from the vaccine production facility of Finlay
Institute, Cuba and contained the major outer membrane
proteins (OMP) P1 (Por A), P3 (Por B) and P5 plus other
high MW OMP proteins from 65 to 95 KDa, lipopolysac-
charide (LPS) (2–6% of total protein content) and bacte-
rial phospholipids as principal components. AFCo1
shows a multilayered tubular structure and conserves all
components of PL but in a completely new structure with
additional properties [32,35].
SCS shares structural similarities with AFCo1, but instead
of being generated from N. meningitidis serogroup B PL, it
was generated from negatively charged lipid membrane
prepared from cholesterol and phosphatidyl serine as
detailed below. CFA (Difco, Laboratories, Detroit, MI)
was prepared and formulated with antigen following the
manufacturer's instructions.
Antigen incorporation into AFCo1 or SCS
AFCo1 was obtained from PL using a rotary dialysis sys-
tem as previously described [31]. Briefly, PL was resus-
pended at 1 mg/mL in Tris (30 mM) – EDTA (3 mM)
buffer containing 1.5% sodium deoxicolate (DOC). The
solution was pulse sonicated for 5 min in ice and the
resulting transparent solution was dialysed 24 h against a
buffer containing 5 mM of CaCl2. During the dialysis
process, the DOC was removed allowing the formation of
AFCo1 by the interaction of divalent cations with the lipid
membranes of PL. SCS were obtained from lipid vesicles
containing phosphatidyl serine and cholesterol (9:1).
Briefly, cholesterol was dissolved in a solution of phos-
phatidyl serine in chloroform, vacuum dried under nitro-
gen and resuspended in Tris buffer (30 mM). The solution
was then dialysed against Ca2+ buffer under the same con-
ditions used for making AFCo-1. MSP4 and MSP5 incor-
poration into AFCo1 or SCS was performed in
independent batches by the same methodology but add-
ing the proteins into the PL or lipid vesicles solutions (1:2
ratio proteins/PL or 1:2 ratio proteins/synthetic lipo-
somes, respectively) before dialysis. The dialysis products
were centrifuged and the pellet was then resuspended in
dialysis buffer. The incorporation of MSP4 and MSP5 into
AFCo1 and SCS was confirmed by SDS-PAGE and western
blotting. The efficiency of the incorporation process into
AFCo1 or SCS was over 85% for both proteins. Protein
concentration was measured by BCA assay kit (Sigma) fol-
lowing the manufacturer's instructions and adjusted for
immunization experiments.
Animal experiments
The immunogenicity of the different formulations con-
taining MSP4 or MSP5 was assessed using female BALB/c
mice of 60–100 days of age. Mice were randomly distrib-
uted into four groups of 10, and immunized at 14-day
intervals with three doses of 10 μg MSPs (all groups
received the same amount of MSP): Group 1 was immu-
nized with MSP in PBS, groups 2 and 3 received MSP
incorporated into SCS (MSP-SCS) or AFCo1 (MSP-
AFCo1) respectively, and group 4 received the MSP emul-
sified in CFA (MSP-CFA). Delayed-type hypersensitivity
reactions (DTH) were assessed 21 days after the last
immunization. Serum samples were taken at 21 and 35
days after last immunization. On day 45, mice were sacri-
ficed and spleen cells were obtained for proliferation
assays and cytokine determination. MSP4 and MSP5 pro-
teins were studied independently in two different experi-
ments but following the same design as described above.
Serum antibody measurement
MSP and PL-specific IgG antibodies were determined by
standard ELISA protocols. In brief, ELISA plates were
coated overnight at 4°C with MSP 2 μg/mL or PL 10 μg/
mL. Mouse serum samples in duplicate were used at 1/
1000 dilution and incubated in ELISA plates for two hours
at room temperature (RT). HRP-conjugated monoclonal
antibodies (Pharmingen) were used to detect total anti-
gen-specific IgG, IgG1, or IgG2a. TMB (3,3',5,5'-tetrame-
thylbenzidine) was used for a readout and absorbanceMalaria Journal 2009, 8:35 http://www.malariajournal.com/content/8/1/35
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read at 450 nm after stopping with 1 M H2SO4. Titers were
expressed as arbitrary units read from an internal lab-
derived standard curve.
Delayed-type hypersensitivity reaction
DTH reactions were assayed against MSP4 or MSP5 inde-
pendently in the footpad of immunized mice. Antigens
were prepared in PBS (0.1 mg/mL) and 50 μL was injected
intradermally (5 μg) in the left footpad using a 30 G nee-
dles. The same volume of PBS was injected into the right
footpad as a control. The presence of footpad reactions
was checked at 15 min, 4 h and 24 h. The extent of inflam-
mation in the footpad was measured 48 h after injection
using a spring gauge calliper. Antigen-specific DTH was
accessed as the mean of the difference of thickness
between the left (antigen) and right (PBS) footpad.
Spleen cell proliferation assay
The induction of memory T and B cells was assessed in
vitro by proliferation of spleen cells in response to MSP
stimulation. Proliferation was detected by dye dilution
method of CFSE stained cells, as previously described
[35,36]. Briefly, mice were sacrificed by cervical disloca-
tion and the spleens were aseptically removed. Spleen
cells were harvested by flushing the spleen with PBS. Red
blood cells were eliminated by treatment with a hyper-
tonic solution of NH4Cl for three minutes on ice followed
by centrifugation and washing. Cells were stained with
CFSE (2 μM) for 10 min at 37°C, washed three times with
PBS containing 20% foetal calf serum (FCS), and resus-
pended at 8 × 106 cells/mL in RPMI-1640 medium supple-
mented with L-glutamine, pyruvate, gentamicin,
penicillin and 10% FCS. Cells were culture in 24-well
plates (8 × 106 cells/well, 2 mL/well) in the presence of
MSP (10 μg), PHA (5 μg), hepatitis B surface antigen (5
μg) or medium (background control). After five days of
culture, cells were harvested and analysed for proliferation
using FACScanto cytometer (Becton Dickinson). Prolifer-
ating cell populations were identified by staining with
CD4, CD8 or CD19 PE-labelled monoclonal antibodies
(Pharmigen). Culture supernatants were collected for
cytokine determination.
Cytokine assay
The production of IFNγ and IL5 by proliferating spleno-
cytes was measured in the culture supernatant by ELISA.
Capture and peroxidase-conjugated detection antibodies
(Pharmigen) were used according to the manufacturer's
instructions. The quantities of each cytokine were deter-
mined using standard curves with recombinant IFNγ or
IL5.
Statistical analysis
Descriptive statistical variables (mean and standard devi-
ation) were calculated for all data and presented graphi-
cally. Normality of data was analysed using Kolmorgorov-
Smirnov normality test and comparisons between groups
were accessed by one-way ANOVA followed by a Tukey
multiple comparison test. P value of 0.05 was used to
determine significant differences.
Influence of adjuvant on anti-MSP4 and MSP5 IgG production Figure 1
Influence of adjuvant on anti-MSP4 and MSP5 IgG production. The adjuvant effect of AFCo1, SCS or CFA on the 
immune response against MSP4 or MSP5 was explored in separated immunization experiments. Mice were injected with three 
intramuscular doses at a 14-day interval of MSP4 or MSP5 incorporated into AFCo1 or SCS, or mixed with CFA or PBS. Serum 
samples were taken 21 days after the last immunization, MSP4 (Panel A) or MSP5 (Panel B)-specific IgG were measured by 
ELISA. Antibodies levels are expressed as a logarithm of the titer. Each experiment was repeated 3 times. The means and 
standard deviations are showed. * Significant differences by Tukey test (p < 0.05) compared with PBS group.
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Results
MSP-specific IgG responses and subclass composition
In two separate experiments, mice were immunized intra-
muscularly with 10 μg of MSP4 or MSP5 adjuvated with
CFA, PBS or incorporated into AFCo1 or SCS. Twenty one
days after the third and final immunisation, mice injected
with MSP in PBS had measurable anti-MSP antibodies in
their sera (Figure 1). However, anti-MSP titers were signif-
icantly increased when MSP was administrated in CFA or
AFCo1 with no significant differences between CFA and
AFCo1 induced titers. In contrast, no adjuvant effect was
observed when MSP was incorporated into SCS, with anti-
body titers not significantly different to those seen with
MSP in PBS. The IgG subclass composition of the anti-
MSP response was highly dependant on the adjuvant
used. MSP in PBS or SCS induced exclusively IgG1 anti-
bodies with no measurable IgG2 response, whereas
AFCo1 and CFA induced both high IgG2a and IgG1 sug-
gesting a preferential induction of a Th1-type response,
similar to CFA which also induced high IgG2a and IgG1
(Figure 2).
MSP-specific DTH reaction
The development of DTH skin reactions 48–72 hours after
intradermal injection of a sub-immunizing dose of anti-
gen provides evidence of a cell-mediated or Th1 response.
Based on its ability to induce IgG2a, AFCo1 may induce a
Th1-type immune response. To confirm this possibility,
DTH reactions against MSP were assessed in all experi-
mental groups. As shown in Figure 3, groups immunized
with MSP4 or MSP5 in SCS or PBS did not develop a
detectable DTH reaction following intradermal challenge
with MSP4 or MSP5. In contrast, groups immunized with
MSP incorporated into AFCo1 or adjuvated with CFA
developed strong DTH responses after intradermal chal-
lenge with MSP, in agreement with the increased levels of
MSP-specific IgG2a detected after immunization. The size
of the DTH reaction in mice receiving the AFCo1-MSP for-
mulations was significantly higher than that in the CFA-
MSP injected group.
MSP-specific splenocyte proliferation
CSFE-based spleen cell proliferation assays to MSP were
performed to compare the extent and type of memory T-
cell responses induced by each adjuvant. Mice were sacri-
ficed 45 days after the final immunization and spleno-
cytes isolated and cultured for 5 days in the presence of
MSP, hepatitis B surface antigen (HBsAg) (control anti-
gen), PHA (control mitogen) or medium alone. Prolifera-
tion was only observed when splenocytes were stimulated
in vitro with MSPs or PHA (Figure 4A, Figure 4B) and as
expected no proliferation of splenocyteswas induced by
medium alone or HBsAg control (Figure 4A, Figure 4B).
Splenocytes from mice immunized with AFCo1-MSP or
CFA-MSP showed significantly higher proliferation than
splenocytes from SCS-MSP or PBS-MSP immunized mice.
Although the percentage of proliferating CD4+ T cells was
similar in all groups, differences were detected in CD8+ T-
cell proliferation between adjuvant groups (Figure 4C,
Figure 4D). CFA-MSP and AFCo1-MSP immunized mice
showed significantly increased CD8+ T-cell proliferation
to MSP over SCS-MSP or PBS-MSP immunized groups.
Consistent with the higher levels of MSP-specific IgG anti-
bodies in the AFCo1 or CFA-adjuvanted MSP groups,
there was an increased frequency of B-cell proliferation to
MSP in these groups. Comparing the MSP4 and MSP5
experiments, similar results between groups were
observed with all immunized groups having high CD4+ T
cell proliferation to MSP whereas only the CFA-MSP and
AFCo1-MSP groups had significantly increased CD8+ T-
cell and B-cell proliferation to MSP.
Influence of adjuvant on anti-MSP4 and MSP5 IgG isotype  production Figure 2
Influence of adjuvant on anti-MSP4 and MSP5 IgG 
isotype production. The adjuvant effect of AFCo1, SCS, 
CFA or PBS on the immune response against MSP4 or MSP5 
was compared. Mice were injected with three intramuscular 
doses at a 14 day interval of MSP4 or MSP5 incorporated 
into AFCo1 or SCS, or mixed with CFA or PBS. MSP-specific 
IgG1 and IgG2a were measured by ELISA in serum taken 21 
days after the last immunization. (Panel A) MSP4-specific 
IgG1 (open bars) and IgG2a (lined bars) from MSP4 immu-
nized mice. (Panel B) MSP5-specific IgG1 (filled bars) and 
IgG2a (lined bars) from MSP5 immunized mice. Antibodies 
levels are expressed as a logarithm of the titer. The means 
and standard deviations of 3 different experiments are 
shown. * Significant differences by Tukey test (p < 0.05).).
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MSP-specific cytokine production
MSP-specific cytokine production (IFNγ and IL5) was
measured in the culture supernatants of splenocytes incu-
bated with MSP for 5 days. Splenocytes from mice immu-
nized with CFA-MSP or AFCo1-MSP produced
significantly higher levels of the Th1 cytokine IFNγ in
response to MSP stimulation than splenocytes from SCS-
MSP and PBS-MSP injected mice (Figure 5). MSP-stimu-
lated IL5 production was low in all groups.
Discussion
The results show that AFCo1 is an effective adjuvant that
induces a strong antibody and T-cell immune response to
MSP4 or MSP5 vaccine antigens with potency comparable
to CFA. AFCo1 stimulated high levels of MSP-specific
IgG2a, IFNγ, and CD4+ and CD8+ proliferation consist-
ent with induction of a Th1-type immune response. In
addition, only mice immunized with AFCo1-MSP or CFA-
MSP developed a DTH reaction following intradermal
challenge with MSP. How relevant these observations are
to malaria protection remains to be confirmed in a chal-
lenge model. Unfortunately, only in vitro parasite infectiv-
ity growth inhibition assays are available for P. falciparum.
Thus no definite in vivo correlates of protection are availa-
ble for human malaria. However, Stewart et al similarly
evaluated the adjuvant effect of different formulations of
RTS,S vaccine by DTH and cellular outcomes and sug-
gested that a Th1 response could be a good marker of
effectiveness for adjuvant suitability for malaria vaccine
development [38,39].
Considering the complexity of Plasmodium  life cycle, a
protective immune response should probably include
multiple mechanisms to target different stages. Increased
CD8 T-cell activity against Plasmodium antigens may help
eradicate the intracellular stages of the Plasmodium human
cycle by mechanisms including cross-presentation of par-
asite-derived antigens [40,41]. On the other hand, immu-
nological studies in malaria patients suggest that the level
of antibodies against blood stages of Plasmodium, predicts
recovery from malaria. In addition, in vitro infection inhi-
bition studies have demonstrated that antibodies directed
against MSP1 inhibit parasite infectivity and red blood
cell (RBC) invasion [42], suggesting that MSP proteins
could be promising candidates for vaccine development
[11,30,43]. Even the role of antibody in malaria protec-
tion remains uncertain; some functional properties of
antibodies like specificity, subclass and binding affinity
are likely to be important for parasite elimination.
A combination of antibody-dependent and cell-mediated
mechanisms may provide the most efficient immunity
against Plasmodium infection. Even although antibodies
may be effective against circulating parasites, a T-cell
Delayed type hypersensitivity reaction induced by intradermal challenge with MSP4 or MSP5 in immunized mice Figure 3
Delayed type hypersensitivity reaction induced by intradermal challenge with MSP4 or MSP5 in immunized 
mice. Mice were immunized with MSP4 or MSP5 incorporated into AFCo1 or SCS, or mixed with CFA or PBS (3 intramuscu-
lar doses, 14 day interval). The presence of delayed type hypersensitivity (DTH) was tested 21 days after the last immunization 
by intradermal challenge with 5 μg of MSP4 or MSP5 in the left footpad. PBS was injected in the right footpad as control. The 
size of inflammation in both footpaths was measured 48 h after challenge using a caliper. The induration induced by the antigen 
was measured as the difference of right minus left footpad thickness. The magnitude of DTH reaction induced by MSP4 (Panel 
A) and MSP5 (Panel B) immunization are expressed as the mean and standard deviation of the induration in each experimental 
group. * Significant differences by Tukey test (p < 0.05).
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response is also needed to eliminate intracellular parasites
[44-47]. A Th1 type immune response should be benefi-
cial given the need for complement fixing antibodies and
CTL activity to completely eliminate intracellular parasites
[40]. The induction of a Th1 immune response could pro-
vide an adequate environment for the induction of such
mechanisms. The presence of high levels of IFNγ drive the
production of IgG subclasses with high complement
binding properties like IgG2a, as well as the differentia-
tion and proliferation of CD8+ T cell with potential CTL
activity.
The ability of AFCo1 to induce a Th1-like response has
been previously demonstrated using different antigens,
including the ability to induce a switch from a Th2 to Th1
response [32]. Strong CD4+ T-cell proliferation and high
levels of IFNγ production upon in vitro stimulation of
spleen cells from immunized mice further supports the
Th1 polarizing capability of AFCo1. The results from the
present experiments, confirmed the Th1 polarizing prop-
erties of AFCo1 but using MSPs antigens from P. falci-
parum. This property is comparable with the adjuvant
action of CFA, since only animals from groups receiving
MSP in CFA or AFCo1, showed similar results on the Th1
measuring tests.
Influence of adjuvant on MSP4 or MSP5-induced splenocyte proliferation Figure 4
Influence of adjuvant on MSP4 or MSP5-induced splenocyte proliferation. Splenocytes from mice immunized with 
MSP4 or MSP5 in different adjuvants were isolated, stained with CFSE and cultured in the presence of MSP4 or MSP5 at 10 μg/
ml. HBsAg was used as an unrelated antigen control. PHA and medium alone were used as positive and negative controls 
respectively (data not show). After 5 days, proliferation was detected by the presence of cells with a decreased fluorescence 
intensity compared with the negative control (medium control). The frequencies of MSP4 (Panel A) or MSP5 (Panel B) specific 
proliferating cells are expressed as percentages of the total population. Proliferating populations were identified and quantified 
by gating specific proliferating cells previously stained with anti-CD4, CD8 or CD19 PE labeled monoclonal antibodies. The dis-
tribution of proliferating populations is showed as percentages of the total number of MSP4 (Panel C) or MSP5 (Panel D) stim-
ulated proliferating cells.
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The Th1 adjuvant properties of AFCo1 could be explained
by the presence of strong activators of the immune system
within from the MBOMP like LPS and Porins. These com-
ponents are present in the PL and are conserved during its
transformation into AFCo1. LPS and Porins from B
meningococcus are well known activators of TLR signal-
ling pathways on dendritic cells and conditioning Th1
immune response polarization.
This possibility could be further supported from the com-
parison of the immune response induced by AFCo1 and
SCS. The use of synthetic cochleates as a control showed
that the SCS sharing a similar cochleate structure with
AFCo1, had no adjuvant effect as anti-MSP IgG levels were
no different as to when the antigen was given in PBS. This
suggests that the adjuvant effect of AFCo1 is highly
dependent on the PAMPs from Neisseria rather than the
cochleate structure per se. Furthermore, it could also sup-
port the potential use of bacterial-derived adjuvants for
malaria vaccines development [48,49]. In fact, the two
successful adjuvants in this study, AFCo1 and CFA, both
contain components derived from bacterial membranes
that are able to provide strong immune activation signals
[50,51]. Notably, the CFA-MSP and AFCo1-MSP groups
also showed the highest level of CD8+ T-cell proliferation
to MSP.
Recent data also suggest the ability of parasites to induce
immune regulatory responses during infection that
inhibit host immune defence mechanisms, which adds
another barrier to the development of malaria vaccines
[19]. The presence of Foxp3, CD25+CD4+ T cells has been
reported to correlate with more rapid parasite growth dur-
ing P. falciparurm infection [20]. Regulatory T cells block
the activation of parasite elimination mechanisms and
enable the parasite to escape from host immunity [19,44].
Thus, an ideal adjuvant for use with malaria vaccines must
be capable of inducing a strong Th1-type response and
overcome parasite-induced regulatory mechanisms. The
ability of AFCo1 to specifically abrogate the regulatory
mechanisms induced by Plasmodium remains to be further
explored. In most studies that have shown protection
against parasite challenge, CFA was the adjuvant able to
generate the best protection. Immunisation with MSP4/5
or combinations of MSP4/5 and MSP1, in CFA induced a
high level of immunity that protected mice from lethal
challenge [31,52-54]. Although, no P. falciparurm animals
challenge models closely approximate human infection,
the fact that CFA is able to induce protective immune
response to P. yoelii in mice suggests that a human adju-
vant of equivalent potency may be required to achieve a
successful malaria vaccine.
Conclusion
Considering that CFA induces protective response in ani-
mal models of malaria challenge, the fact that AFCo1 and
CFA induce a similar immune response to MSP in mice
suggests the potential of AFCo1 as a potent adjuvant for
human malaria vaccines, particularly given that the con-
stituents of AFCo1 are already approved for human vac-
cine use.
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Panel A shows the levels of IFNγ and IL5 produced by spleen 
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CFA after in vitro recall with MSP4; whereas panel B shows 
the levels of IFNγ and IL5 produced by spleen cells from mice 
immunized with MSP5 in AFCo1, SCS, PBS or CFA after in 
vitro recall with MSP5. The means and standard errors are 
shown. * Significant differences by Tukey test (p < 0.05).
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